|  | AMG 108 | |||
---|---|---|---|---|---|
 | Placebo (n= 203) | 50 mg (n= 204) | 125 mg (n= 203) | 250 mg (n= 203) | Total (n= 610) |
Mean age (years) | 52.1 | 51.4 | 51.7 | 52.2 | 51.8 |
Age group, n (%) | Â | Â | Â | Â | Â |
   < 65 years | 185 (91.1) | 171 (83.8) | 176 (86.7) | 184 (90.6) | 531 (87.0) |
   ≥65 years | 18 (8.9) | 33 (16.2) | 27 (13.3) | 19 (9.4) | 79 (13.0) |
Female, n (%) | 158 (77.8) | 155 (76.0) | 163 (80.3) | 160 (78.8) | 478 (78.4) |
Ethnicity, n (%) | Â | Â | Â | Â | Â |
   White | 168 (82.8) | 169 (82.8) | 177 (87.2) | 179 (88.2) | 525 (86.1) |
   Hispanic | 27 (13.3) | 24 (11.8) | 18 (8.9) | 17 (8.4) | 59 (9.7) |
   Othera | 8 (3.9) | 11 (5.4) | 8 (3.9) | 7 (3.4) | 26 (4.3) |
Mean weight (kg) | 76.4 | 77.2 | 74.2 | 75.0 | 75.4 |
Mean height (cm) | 164.0 | 164.6 | 164.0 | 164.8 | 164.5 |
Mean body mass index (kg/m2) | 28.4 | 28.4 | 27.5 | 27.5 | 27.8 |
Mean duration of RA (years) | 7.6 | 7.3 | 7.5 | 8.0 | 7.6 |
Subcomponent of ACR (mean) | Â | Â | Â | Â | Â |
   Tender joint count | 26.3 | 26.5 | 24.8 | 26.9 | 26.1 |
   Swollen joint count | 16.8 | 16.8 | 15.8 | 15.7 | 16.1 |
   Patient global assessment | 5.9 | 6.2 | 6.1 | 6.1 | 6.2 |
   Physician global assessment | 6.2 | 6.3 | 6.3 | 6.5 | 6.4 |
   Patient pain assessment | 51.2 | 53.9 | 53.5 | 57.0 | 54.8 |
HAQ Disability Index | 1.4 | 1.5 | 1.5 | 1.5 | 1.5 |
C-reactive protein (mg/dl) | 1.2 | 1.8 | 1.5 | 1.4 | 1.6 |
ESR (mm/hour) | 33.4 | 40.1 | 35.6 | 35.5 | 37.1 |
Mean DAS28 CRP | 4.7 | 4.9 | 4.7 | 4.8 | 4.8 |
Mean DAS28 ESR | 5.3 | 5.4 | 5.3 | 5.4 | 5.3 |
Mean tender joint count (28 joints) | 14.0 | 14.5 | 13.5 | 14.0 | 14.0 |
Mean swollen joint count (28 joints) | 11.3 | 10.6 | 10.8 | 11.2 | 11.0 |